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ABSTRACT 
MITOCHONDRIAL TARGETING OF THE PRO-APOPTOTIC PROTEIN BAX 
Stephanie Erin Brock 
July 08, 2009 
Here, I address the function of the carboxy-terminal hydrophobic helix of 
the pro-apoptotic protein Bax. There has been considerable controversy as to 
whether this sequence is required for the targeting and insertion of Bax into the 
mitochondrial outer membrane. The Bax carboxy-terminal tail is tucked into a 
hydrophobic pocket within the closed/inactive conformation of Bax. Apoptotic 
stimulation results in an opening of the Bax conformation, exposing a 
mitochondrial-targeting signal and subsequent insertion of Bax into the 
mitochondrial outer membrane. Here, I confirm that the Bax tail alone can 
specifically target and anchor a cytosolic passenger protein to the mitochondria. 
Surprisingly, however, I find that the carboxy-terminal tail is not responsible for 
the specific targeting of Bax to the mitochondria rather than other cellular 
membranes. Specifically, replacing the Bax tail with an ER-targeting tail-anchor 
had no effect on Bax mitochondrial targeting, in the context of full-length Bax. 
This contrasts to the targeting function of tail-anchor signals in other tail-
anchored proteins. In addition, I demonstrated that the Bax tail has a negative 
IV 
regulatory effect on Sax activation. Mutations that disrupt the interaction of the 
Sax tail with the hydrophobic pocket resulted in an open/active conformation of 
Sax and constitutive mitochondrial targeting. Deletion of the Sax tail also 
resulted in an open/active conformation of Sax, however the anchor-deleted form 
of Sax was not associated with mitochondria. This indicates a requirement of the 
Sax tail for mitochondrial translocation. Sy introducing charged residues into the 
tail sequence to block insertion of the sequence into the hydrophobic bilayer, I 
show that insertion of the Sax tail is required for Sax mitochondrial targeting. My 
data support a model whereby the Sax tail must be released from its hydrophobic 
pocket to initiate the change into an open/active conformation. The tail then 
functions as an anchor to stabilize Sax at the mitochondrion after the initial 
addressing step. 
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Apoptosis is an important process whereby cells can induce their own 
demise. It is carried out by specific pathways in the cell that are tightly-regulated. 
This process of cell suicide was first described in 1842 by Carl Vogt, but wasn't 
cOined "apoptosis" until 1972 by John Kerr Kerr JF, 1972. Programmed cell death is 
essential for the specific cell turnover in developmental processes as well as in 
tissue homeostasis. It is also important in the elimination of damaged or infected 
cells Strasser A, 2000. Cells undergoing apoptosis display very distinct 
characteristics. These include cell shrinkage, chromatin condensation, DNA 
fragmentation, membrane blebbing, and exposure of phosphatidyl serine on the 
outer leaflet of the plasma membrane. Apoptotic cell death is stimulated by two 
distinct pathways (Figure 1). One pathway is triggered by death receptors at the 
cell surface. The other pathway is initiated by cellular stress signals. Both 
pathways ultimately result in activation of proteases known as caspases. The 
death receptor pathway involves activation of death receptors including TNF, Fas 
and TRAIL receptors Ashkenazi A, 1998. Stimulation by the respective death ligands 
triggers a signaling cascade within the cell. This leads to activation of caspases 
by triggering a specific proteolytic cleavage of the inactive procaspases to 
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Figure 1. Two main pathways to apoptosis. Intracellular stress signals are 
mediated through the Bcl2 family, whereas the death-receptor pathway is 
activated by signals from other cells. Activity of caspase-9 and caspase-3 is 
restrained by inhibitor of apoptosis proteins (lAPs), but the lAPs can be 
countermanded by Diablo/Smac and OmilHtrA2, which are released from 
damaged mitochondria. Apaf1, apoptotic protease-activating factor 1; cyt c, 
cytochrome c; FADD, Fas associated death-domain; FasL, Fas ligand; TNF-a, 





produce active enzymes. These caspases then act as the executors of cell 
death. Caspase substrates include apoptotic proteins, inhibitors of apoptotic 
proteins, DNA repair enzymes, structural proteins, and negative regulators of 
endonucleases Strasser A, 2000. The stress pathway is initiated by intrinsic stress 
signals (eg. DNA damage, oxidative stress, ER stress) or by outside signals (eg. 
growth factor withdrawal, irradiation, cytotoxins). Apoptosis is dependent on the 
mitochondria in this pathway Jin Z, 2005. The BcI-2 family of proteins deciphers and 
transfers these death signals to the mitochondria, inducing the release of 
apoptogenic factors (eg. Cytochrome c) from the mitochondria into the cytosol 
Green DR, 1998. Cytochrome c then interacts with Apaf-1 to form the apoptosome 
complex. The apoptosome cleaves pro-caspase-9 to activate caspase-9, 
initiating the caspase activation cascade. 
The apoptotic machinery must be kept in check, so that aberrant cell 
death does not occur Strasser A, 2000. Inhibitors of apoptosis are found throughout 
both the death receptor and stress-signal pathways. Examples include the lAPs 
(inhibitors of apoptosis) that bind and inhibit caspases, and the anti-apoptotic 
members of the bcl-2 family (bcl-2, bcl-xL) that inhibit the pro-apoptotic bcl-2 
members (bax, bak). The Bcl-2 family will be described in greater detail in the 
next section. De-regulation of the apoptotic process is involved in a variety of 
disease states. When apoptosis is running un-checked, abnormal amounts of 
cell death occur. This can lead to neurodegeneration or cardiac disease. On the 
other hand, when apoptosis is not activated when cued, infected or damaged 
4 
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cells can accumulate. This can lead to states of tumorigenesis or autoimmune 
disease. 
The Bcl-2 family of proteins 
The BcI-2 protein was identified in 1984 where it was found to be 
aberrantly overexpressed in human B-cell lymphoma due to a chromosome 
translocation Tsujimoto Y, 1984. Further studies showed that it was functioning in the 
inhibition of apoptosis in these cells. Following the identification of BcI-2, various 
proteins containing homologous domains were discovered Adams JM, 1998. These 
are shown in Figure 2. These proteins contain conserved domains referred to as 
bcl-2 homology domains (BH1, BH2, BH3 or BH4). Most members of this family 
contain multiple homology domains, whereas some of these proteins contain only 
the BH3 domain. The BcI-2 protein family plays a central role in the stress-signal 
pathway of apoptosis Cory s, 2002. Some of the BcI-2 proteins induce apoptosis, 
while others inhibit apoptosis. The anti-apoptotic members all contain at least 3 
of the BH domains, and include proteins such as BcI-2, Bcl-xL, and Mcl-1. The 
pro-apoptotic members include multi-domain proteins (ie. Bax and Bak), as well 
as BH3-only proteins (ie. Bid and Bim). Various members of the BcI-2 family can 
interact with themselves, as well as with other BcI-2 family members. These 
interactions are mediated via the BH3 domain Adams JM, 1998. These intricate 
interactions determine whether or not the cell will undergo apoptosis (Figure 3). 
The anti-apoptotic Bcl-2 proteins can heterodimerize with the pro-apoptotic BcI-2 
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Figure 2. The Bcl-2 family. Three subfamilies are indicated: The BcI-2 cohort 
promotes cell survival, whereas the Bax and BH3 cohorts facilitate apoptosis. 
BH1 to BH4 are conserved sequence motifs. The Bax subfamily resembles the 
Bcl-2 subfamily but lacks a functional BH4 domain. Except for the BH3 domain, 
the BH3 subfamily is unrelated to BcI-2. All proteins compared are mammalian 
(usually human), except for NR-13 (chicken), CED-9, and EGL-1 (C. elegans) , 
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Figure 3. Interactions of the Bcl-2 family in initiating apoptosis. 
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activators of the pro-apoptotic Bcl-2 proteins by direct interaction or indirectly by 
interacting with and inhibiting the anti-apoptotic Bcl-2 proteins. 
Proteins within this family are localized primarily at the mitochondria, but 
also to some extent at the endoplasmic reticulum (Figure 4). While some Bcl-2-
family proteins are constitutively localized to their respective membranes, some 
require conformational changes or posttranslational modifications to translocate 
to membranes Schinzel A, 2004. Posttranslational modifications include 
phosphorylation/dephosphorylation, proteolytic cleavage, release from inhibiting 
proteins, or dissociation from intracellular structures. 
Role of Sax in apoptosis 
Bax was discovered by Dr. Stanley Korsmeyer's group in the early 1990's 
Oltvai ZN, 1993. In Korsmeyer's study, Bax was identified due to its interaction with 
Bcl-2. Although Bax is similar in structure to BcI-2, Bax was found to work in 
opposition to BcI-2 and promote apoptosis. Bax and its closely-related Bcl-2 
family member, Bak, playa redundant role in triggering apoptosis. The presence 
of one or the other is essential for the intrinsic apoptotic pathway Cheng EH, 2001; Wei 
MC, 2001; Zong WX, 2001. Mutation or deletion of Bax results in a small impairment of 
the apoptotic-inducing ability of cells, whereas disruption of Bak function does not 
exhibit any effects on apoptosis. However, inactivation of both Bax and Sak 
conveys resistance to various apoptotic stress stimuli in a variety of cell lines. 








Figure 4. Localization and posttranslational modifications of Bcl-2 
proteins. Posttranslational modification is required for the translocation of certain 
multidomain and BH3-only Bcl-2 family members, whilst some proteins are 
directly targeted to and inserted into the mitochondrial outer membrane (MOM) 
and/or the ER membrane (Bak, BcI-xL and BcI-2). In response to an apoptotic 
stimulus, BH3-only proteins (yellow) translocate to interact with multidomain Bcl-
2 family members on the MOM. Bim and Bmf dissociate from cytoskeletal 
structures, Bad from 14-3-3 and Bid is proteolytically cleaved. Bax and BcI-w 
undergo a conformational change, which allows them to translocate and/or insert 
into the MOM. 
11 
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In the normal state of cells, Sax is found as a soluble monomer within the 
cytosol. This conformation of Sax consists of a bundle of 9 a-helices (Figure 5) 
Suzuki M, 2000. The C-terminal tail (a-helix9) of Sax is tucked within a hydrophobic 
pocket. Within this pocket, the Sax tail functions to hide two important domains, 
the SH3 domain and a-helices 5 and 6. The SH3 domain is essential for Sax 
activity due to its requirement for oligomerization. Helices 5 and 6 are 
considered to be the "pore-forming domain" of Sax Annis MG, 2005. Upon apoptotic 
induction, Sax trans locates to a mitochondrial-bound form Hsu YT, 1997; Wolter KG, 1997; 
Goping IS, 1998; Hsu YT, 1998; Nechushtan A, 1999; Hou Q, 2005 Translocation is due to a 
conformational change of Sax, resulting in a more open structure and exposure 
of a mitochondrial-targeting signal. This open conformation of Sax can be 
detected using a conformation-specific antibody (termed 6a7) that binds to an N-
terminal epitope. This epitope is normally hidden in the closed conformation of 
Sax Hsu YT, 1998; Hsu YT, 1997; Yethon JA, 2003. The mitochondrial-bound form of Sax 
consists of insertion of the putative "pore-forming domain" a-helices 5 and 6, and 
the C-terminal tail a-helix9 Annis MG, 2005. This was determined by chemically 
labeling residues within the potential transmembrane sequences of a-helices 5, 
6, and 9. A membrane-impermeant modifying agent was then used to probe for 
the chemical labels. Insertion within the bilayer protected against modification of 
the chemical labels. At the mitochondrial outer membrane (MOM), Sax homo-
oligomerizes and stimulates the release of apoptotic factors such as cytochrome 
c from the mitochondria Antonsson S, 2000; Antonsson S, 2001; Annis MG, 2005; Sharpe JC, 2004; 
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Figure 5. Structure of Bax. A ribbon representation of an averaged minimized 
NMR structure for the closed conformation of Bax. Helices are distinguished by 
different colors. Residues 816- A35, A54-D71, M74-A81, R89-M99, G108-C126, 
P130 E146, L149-D154, W158-Y164, W170-W188 make up helices a1, a2, a3, 
a4, a5, a6, a7, a8, a9, respectively. a-helix9 is designated by lime green. 
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the formation of the oligomeric apoptosome complex. The apoptosome complex 
promotes activation of caspases in the cell, resulting in cell death. 
Bax has been widely studied, yet the details of its activation remain 
unclear. Addition of an apoptotic cytosolic extract can induce Bax translocation 
to mitochondria in vitro. This supports the notion that soluble cytosolic factors 
can activate Bax Goping IS, 1998; Nomura M, 1999. Many apoptotic stimuli that induce Bax 
activation have been identified, yet the mechanisms that lead to this activation 
remain to be elucidated. One generally accepted model is that the BH3-only BcI-
2 family members, such as Bid and Bim, interact directly with Bax, leading to Bax 
activation Kuwana T, 2005; Eskes R, 2000; Desagher S, 1999; Marani M, 2002; Roucou x, 2002. However, 
other activation mechanisms, and control of Bax activation, appear to operate as 
well Ruffolo SC, 2000; Wu Y, 2007. Proteins including Ku70, humanin, and 14-3-3 have 
been identified to interact with Bax and inhibit Bax translocation and activation 
Sawada M, 2003; Guo S, 2003; Nomura M, 2003. Anti-apoptotic Bcl-2 family proteins such as 
Bcl-2 and Bcl-xL also act to prevent Bax conformational change, translocation, 
oligomerization and activity Jurgensmeier JM, 1998; Finucane OM, 1999; Murphy KM, 2000; Yi X, 2003; 
Antonsson S, 2001; Dlugosz PJ, 2006; Billen LP, 2008. Therefore, activation of Bax could be partly 
due to disruption of these inhibitory interactions. Known activators and inhibitors 
of Bax are displayed in Figure 6. Bax inserted at the membrane can also act to 
recruit cytosolic Bax to the mitochondria. This autoactivation leads to a positive 
feedback loop after initial Bax targeting Billen LP, 2008. 
Bax action at the MOM is also incompletely understood. One model 
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Figure 6. Known activators and inhibitors of Bax. 
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for the release of apoptotic factors. Specifically, Sax has been shown to interact 
with the voltage-dependent anion channel (VDAC or porin) and the adenine 
nucleotide translocator (ANT). These two channels comprise the permeability 
transition pore (PTP) of the mitochondria Marzo I, 1998; Narita M, 1998; Brenner C, 2000; Capano M, 
2002; Belzacq AS, 2003. According to this model, Sax cooperates with these channels 
to allow for passage of apoptotic components through the pores. However, the 
detection of these Sax interactions with the PTP have been challenged Eskes R, 
1998; Finucane DM, 1999; Antonsson B, 2001; Mikhailov V, 2001. Specific blocking of the PTP does 
not inhibit Sax-induced release of cytochrome c in vitro Eskes R, 1998. These results 
support a second model in which Sax oligomerization alone leads to direct pore 
formation allowing for release of these factors. During apoptosis, Sax is found in 
an oligomeric state at the MOM. This oligomerization is mediated by the SH3 
domain of Sax Antonsson B, 2001; Zha H, 1996; Wang K, 1998. In vitro studies have shown that 
Sax oligomers can form pores in artificial membranes Adams JM, 1998; Antonsson B, 1997; 
Schlesinger PH, 1997; Antonsson B, 2000; Saito M, 2000. Sax oligomers can also mediate the 
release of cytochrome c from isolated mitochondria, whereas monomeric Sax 
cannot. In addition, a glycoprotein, clusterin, specifically blocks Sax 
oligomerization, subsequently inhibiting Sax-induced apoptosis Zhang H, 2005 
These data indicate that Sax oligomerization is essential for the release of 
apoptotic factors from the mitochondria. 
For the most part, Sax specifically translocates to the mitochondria. 
However, a small portion of Sax can also localize to the endoplasmic reticulum 
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Figure 7. Sax and Sak localized to the ER can initiate apoptosis. In addition 
to their mitochondrial localization and activity, Sax and Sak also reside at the ER. 
Upon ER stress treatment, Sax and Sak can initiate apoptosis from the ER. 
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and oligomerization of Bax at the ER. This subsequently induces caspase 12 
cleavage and apoptosis Zong WX, 2003; Adams JM, 1998. Studies have shown that Bax 
can regulate Ca2+ storage of the ER. This can then increase the Ca2+ uptake into 
the mitochondria, thereby triggering apoptosis Nutt LK, 2002; Nutt LK, 2002; Scorrano L, 2003; 
Oakes SA, 2005. A direct interaction of Bax with the ER transmembrane protein, 
IRE1a, has also been detected. IRE1a mediates the unfolded protein response 
(UPR) of the ER Hetz C, 2006. Therefore, it seems that depending on the upstream 
apoptotic stimulus, Bax can translocate to the mitochondria or the ER to induce 
apoptosis (Figure 8) Scorrano L, 2003. 
Bax in disease states 
Because Bax is a key determinant in cell death, Bax inactivation or over-
activation has been implicated in a variety of disease states (Figure 9). 
Impairment of Bax-induced apoptosis can lead to autoimmune disease or 
oncogenesis. Bax conditional deletion results in an increased number of B cells 
and results in severe autoimmune disease in adult mice Takeuchi 0,2005. The role of 
Bax in tumorigenesis has been studied to a much greater extent. Analysis of Bax 
expression and Bax function in a variety of different cancer cells indicates that 
Bax possesses tumor-suppressor function. Bax expression was shown to be 
downregulated in hepatocellular carcinomas as well as in breast cancer Beerheide W, 
2000; Bargou RC, 1995 Frameshift mutations, missense mutations, and/or single 
amino-acid substitutions have been detected in colorectal cancers, 
gastrointestinal cancers, hematopoietic malignancies, stomach cancers, and 
20 
FIGURE 8. 
Scorrano L. 2003 
Figure 8. Schematic representation of BAXIBAK control points of 
apoptosis at level of ER Ca2+ or mitochondria and categories of stimuli that 






t Bax-induced apoptosis 
Figure 9. Bax in disease states. 
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Oncogenesis 
endometrial cancers Rampino N, 1997; Gil J, 1999; Yamamoto H, 1997; Meijerink JP, 1998; Ouyang H, 1998. 
Cells deficient in Sax expression, including epithelial cancer cells and colon 
carcinoma cells, displayed resistance to multiple apoptotic-inducing stimuli and 
anti-cancer agents Zhang L, 2000; LeBlanc H, 2002; Theodorakis P, 2002. Additionally, Sax 
deficiency in mice displayed increased tumor growth and decreased apoptotic 
ability Yin C, 1997. These results designate Sax as a possible therapeutic target in 
oncogenesis. Initial studies have produced promising results of the therapeutic 
potential of Sax. Exogenous overexpression of Sax increased apoptotic 
induction sensitivity in breast and pancreatic cancer Sakakura C, 1996; Wagener C, 1996; Xu 
ZW, 2002 Furthermore, overexpression of Sax using adenoviral delivery or 
tetracycline-dependent expression resulted in increased apoptosis and tumor 
regression in prostate cancer, lung cancer, and breast cancer mouse models Li X, 
2001; Kagawa S, 2000; Lowe SL, 2001 
Aberrant amplification of Sax-induced apoptosis can cause 
neurodegenerative or cardiac disease states. Increased levels of Sax have been 
found in a variety of neurological disorders including Alzheimer's disease, 
Parkinson's disease, and Huntington's disease. Studies have shown that 
Alzheimer's disease is associated with overexpressed levels of Sax, resulting in 
increased neurodegeneration Paradis E, 1996; Su JH, 1997; Tortosa A, 1998. In a transgenic 
mouse model of Huntington's disease, Sax was overexpressed in affected areas 
of the brain and correlated with increased levels of apoptosis compared to 
controls Teles AV, 2008. Abnormal overexpression of Sax is also seen in brain tissue 
of deceased Parkinson's disease patients compared to tissue from control 
23 
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patients Vila M, 2001. It should be noted that it is difficult to distinguish cause and 
effect of Sax overexpression and nuerodegeneration in these studies. However, 
deletion of Sax increases resistance to neural cell death in a Parkinson's disease 
model, suggesting that Sax could be a therapeutic target in neurodegenerative 
disorders Vila M, 2001; Perier C, 2007. Sax is also a potential therapeutic target for heart 
disease Haunstetter A, 1998; Haunstetter A, 2000. Activation and translocation of Sax is 
detected during cardiac ischemia/reperfusion Lundberg KC, 2004; Hou Q, 2005; Capano M, 2006; 
Gupta S, 2005 Furthermore, absence of Sax results in increased resistance to 
ischemialreperfusion in mouse hearts Hochhauser E, 2003. In Sax homozygous 
knockout mice (-/-) , significant protective effects with ischemia/reperfusion 
treatment, as well as resistance to myocardial infarction, were detected 
compared to Sax homozygous wild-type mice (+/+) Hochhauser E, 2007; Hochhauser E, 2003. 
Bax mitochondrial targeting and the C-terminal tail 
The principle action of Sax is at the mitochondrial membrane. The 
mechanisms that target Sax to the mitochondria remain a matter of controversy. 
In particular, there is disagreement about the role of a hydrophobic alpha 
helix (a-helix9) at the carboxy-terminus of Bax in Bax targeting and 
activation. The Sax tail is tucked in a hydrophobic pocket within the 
inactive/closed conformation of Sax (Figure 10) Suzuki M, 2000; Cartron PF, 2005; Arokum H, 
2004 Upon Sax activation, a conformational change results in release of the tail 
from the pocket. This exposes the previously hidden SH3 domain and 
transmembrane a-helices 5 and 6. This conformational change also results in 
24 
FIGURE 10. 
Suzuki M, 2000 
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Figure 10. The Orientation of the C-terminal Helix. A close-up view of the Sax 
C-terminal helix and the hydrophobic pocket is shown. The side chains of the 
residues in the C terminal helix are represented by balls and sticks. Magenta 
balls represent oxygen atom in threonines and serine. A surface representation 
of the pocket is colored red, purple, and yellow to represent negative, positive, 
and hydrophobic residues, respectively. 
26 
exposure of a mitochondrial-targeting signal. In one model, upon release from 
the hydrophobic groove, the Bax tail serves as the mitochondrial-targeting signal. 
This is similar to the function of the C-terminal hydrophobic tail-anchors of Bcl-2, 
BcI-xL, and other so-called tail-anchored proteins that will be described in the 
next section Nguyen M, 1993; Kaufmann T, 2003; Borgese N, 2003. In support of this model, the 
Bax C-terminal tail alone is sufficient to target a passenger protein to the 
mitochondria Goping IS, 1998; Schinzel A, 2004. This model is also corroborated with tail 
mutation and deletion studies in full-length Bax Schinzel A, 2004; Wolter KG, 1997; Nechushtan A, 
1999. These studies indicate that the Bax tail can regulate Bax targeting and is 
required for Bax mitochondrial localization. Mutation of a single residue (8184) 
within the Sax tail has significant effects on Bax translocation Nechushtan A, 1999. 
Deletion of this residue or SUbstitution of this serine with a valine results in 
constitutive targeting of Bax to the mitochondria, On the contrary, substitution 
with a charged amino acid (lysine, glutamic acid, aspartic acid) inhibits 
translocation of Bax. Phosphorylation at this serine residue has also been 
detected Gardai SJ, 2004; Xin M, 2005. This phosphorylation is believed to be an 
important physiological regulator of Bax targeting. Specifically, Akt-mediated 
phosphorylation at 8184 inhibits Bax translocation and Bax-mediated apoptosis. 
Mutation of this serine to a non-phoshorylatable residue abrogates this inhibition. 
These findings indicate that the Bax tail alone can regulate Bax targeting. 
Complete deletion of the tail (BaxLlC) inhibits mitochondrial localization and 
abrogates apoptotic activity of Bax Schinzel A, 2004; Wolter KG, 1997. Upon addition of an 
apoptotic stimulus, the apoptotic-inducing ability of BaxLlC is comparable to that 
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of vector alone. These results imply that the Bax tail is essential for Bax 
targeting and function. 
This model has been challenged by reports that the C-terminal tail of Bax 
is dispensible for targeting to the mitochondria and subsequent Bax function 
Cartron PF, 2003; Cartron PF, 2005; Tremblais K, 1999. In addition, contradictory findings show 
that the Bax tail alone cannot target a passenger protein to the mitochondria 
Cartron PF. 2003 This supports an alternative model in which a mitochondrial-
targeting signal is present in Bax outside of the C-terminal tail domain. There 
have been reports suggesting a potential mitochondrial-targeting signal within a-
helix1 in the N-terminal portion of Bax Cartron PF, 2003; Cartron PF. 2005; Bellot G, 2007. This 
N-terminal targeting signal can localize a cytosolic passenger protein to the 
mitochondria. This domain was also shown to interact with the well-
characterized mitochondrial import receptor Tom22 and the import channel 
Tom40 Bellot G, 2007. Deletion of a-helix1 was shown to abrogate Bax mitochondrial 
targeting Cartron PF. 2003. In addition, an a-helix1 peptide could compete for binding 
of Bax to mitochondria in vitro. 
Tail-anchored proteins 
Tail-anchored proteins consist of an N-terminal cytosolic globular domain 
that is tethered to an intracellular membrane by a C-terminal hydrophobic 
transmembrane domain or tail-anchor Wattenberg BW, 2001; Borgese N, 2003; Habib SJ, 2003; , 
Borgese N. 2003. There are a variety of proteins considered to be tail-anchored 
proteins that have been identified and characterized (Table 1). A bioinformatic 
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Tai~anchored protein 
1. Localisation proteins 
Vamp. synaptobrevin family, 
svntaxin family 
Vamp-1B 










SNAREs, mediating events of vesicle 
targeting and fusion 
Unknown 
Protein translocation across endoplasmic 
reticulum 
Co-translational protein giycosylation, 
ribosome-binding 
Sarlp binding 
Docking receptor for signal recognition 
particle 
Binding translocation of mitOChondrial 
precursor proteins 
Binding of inositol 5'-phosphatase 
Dynamin recruitment protein 
Cdc31 binding and binding to spindle pole 
body 
2. EnzYmes and metabolic cofecton 
Dolicolphosphate man nose Transfer of mannose residues onto lipid 
synthase anchor 
Cytochrome b. Electron transfer 
OM cytochrome br; Electron transfer 
Heme oxygenase Electron transfer 
Cytochrome P450 Electron transfer 
Aldehyde dehydrogenase Oxidation of small metabolites and drugs 
Monoamine oxidases Oxidation of small metabolites and drugs 




3. BcI-2 family 
Bax 
Bok, BcI-x." Bak, Bik, Hrk, 
Blk, Bim 
BcI-W, MC!-l, Boo 
BcI-2, B c ~XL 
Glycosylphosphoinositide anchc,r synthesis 






Organelles and vesicles of endomembrane 
system (endoplasmic reticulum) 





Mitochondrial outer membrane 
Mitochondrial outer membrane 
Mitochondrial outer membrane 








Mitochondrial outer membrane 
Mitochondrial outer membrane 
Endoplasmic reticulum Goigi 
Endoplasmic reticulum 
Mitochondrial outer membrane 
Unknown 
Unknown 
Mitochondrial outer membrane and 
endoplasmic reticulum 
Since the biochemical activity of the BcI-2 family of proteins has not yet been defined. there may in fact be only two categories. There 
is already much evidence suggesting that the BcI-2 family of proteins acts by localising each other and other proteins to modulate cell 
death signals: they might then fall into the first category. Note that the endoplasmic reticulum is continuous with the other 
membranes of the secretory system and that tail-anchored proteins, as best illustrated by the SNARES, can be destined for locations 
throughout this endomembrane system. The sorting mechanism involved in this redistribution is not known: however, localisation 
within the endomembrane system depends on both the transmembrane and the cytoplasmic sequences. 
Wattenberg BW, 2001 
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study predicts that there are over 400 such proteins encoded in the human 
genome Wattenberg BW, 2007. The C-terminal transmembrane domain serves two 
essential functions in the localization of tail-anchored proteins Wattenberg BW, 2001; 
Habib SJ, 2003; Borgese N, 2003. First, the transmembrane domain and its flanking 
residues contain the sole targeting signal for specific membrane targeting. 
The tail alone contains sufficient information to specifically target a 
passenger protein to a destination membrane. Second, the C-terminal tail 
serves as an anchor to tether the protein to the membrane. Therefore, this 
signal-anchor is absolutely required for the correct targeting and insertion 
of these proteins. Tail-anchored proteins localize primarily to the endoplasmic 
reticulum or the mitochondria, and to a lesser extent at peroxisomal membranes 
Borgese N, 2003. Initial targeting to the ER can be followed by transport to a variety of 
other cellular sites by vesicular trafficking. Some proteins are localized 
exclusively at a single membrane. Others, such as BcI-2, are more broadly 
distributed. The targeting signal within the C-terminal tail that differentiates 
between membranes does not consist of specific amino acid sequences. 
Instead, distinctive structural characteristics of the tail allow for differential 
targeting (Table 2). These characteristics include hydrophobicity, polarity, 
charged flanking-residues, and spacing of residues Borgese N, 2001; Horie C, 2002; Isenmann 
S, 1998; Habib SJ, 2003; Borgese N, 2007; Wattenberg BW, 2007. ER-targeted tail-anchored proteins 
contain relatively hydrophobic transmembrane sequences. 

















GFP-G3S5S7T9GI2 EGFP-LGMDELYKSGSGSKLLGLSLSLTLLGLLLLKKKLLPKS +++ 
GFP-mS5S7G 12 







eGW-LGMDEL YKSGSGSKLLGLSLSLLLLGLLLLKKKLLPKS +++ 
eGI-P-LGMDEL YKSGSGSKLLGLLLSLTLLOLLLLKKKLLPKS ++ 
eGI-P-LGMDEL YKSGSGSKLLGLLLSLLLLGLLLLKKKLLPKS -(endoplasmic 
reticulum) 
eGf-P-LGMDEL YKSGSGSKLLGLSLSL lLLGLLLLKAKLLPKS ++ 
eGf-P-LGMDEL YKSGSGSKLLGLSLSL TLLGLLLLKAAAKA ++ 
eGI-P-LGMDEL YKSGSGSKLLGLSLSLTLLGLLLLKAAK ++ 
eGI-P-LGMDELYKSGSCiSKLLGLSLSLTLLGLLLLKAKA ++ 
eGI-P-LGMDEL Y KSG SOS KLLGLSLSLTLLGLLLLKK +/-(endoplasmic 
reticulum) 
Shown are the names given to constructs (column II the sequence of the sequence of (,-terminus of each 
construct and a summary of localizati(ID experiments for each con.~truct. In bold type are positively charged 
residues. Underlined is the presumptive transmembrane sequence 
Wattenberg BW, 2007 
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transmembrane domains due to the presence of polar residues or due to 
containing shorter transmembrane segments. The mitochondrial-targeting tail 
anchors also contain positively-charged residues that flank the transmembrane 
sequence. Because the C-terminal sequence is the final portion of the protein to 
exit the ribosome during translation, targeting to the destination membrane is 
post-translational. Due to the hydrophobic nature of the tail-anchor, the tail is 
most likely bound by a cytosolic factor, such as a molecular chaperone, upon 
release from the ribosome (Figure 11) Lan L, 2000; Wattenberg BW, 2001. In the case of 
Sax, the protein itself acts as its own chaperone, whereby the CRterminal 
tail folds into a hydrophobic pocket within Sax Suzuki M, 2000. It has not yet 
been established whether a proteinaceous component directly acts as a receptor 
for tail-anchored proteins at the membrane Kim P, 1997; Stefanovic S, 2007; Ahting U, 2005; 
Wattenberg BW, 2001. Some studies have shown that pre-treating membranes with 
proteases abolishes targeting, while others have shown that this pre-treatment 
has no effect. In addition, potential membrane receptors have been identified. 






Wattenberg BW, 2001 
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Figure 11. Stages of targeting tail-anchored proteins to mitochondria. 
Nascent tail-anchored proteins can fold co-translationally in the cytoplasm and, to 
keep the polypeptide soluble in the cytosol, the hydrophobic tail-segments might 
interact with factors such as molecular chaperones (green). The identity of the 
soluble factor(s) is not known, but they might include general molecular 
chaperones such as HSP70, which are involved in the targeting of other protein 
precursors to the endoplasmic reticulum and mitochondria. Facilitation of tail-
anchor insertion into the membrane mayor may not involve the TOM complex. 
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Localization of Bax to the mitochondria is an essential step in Bax-
mediated apoptosis. However, the mechanisms that facilitate this 
translocation are not well-understood. It has generally been accepted that 
Bax is a tail-anchored protein. According to this view the C-terminal 
transmembrane domain facilitates targeting and anchoring of Bax to the 
mitochondria. However, contradictory results have made the role of the 
Bax tail in mitochondrial targeting a matter of debate. In light of these 





MATERIALS AND METHODS 
Mouse embryonic fibroblasts (MEFs) and Hela cells were grown in 
Dulbecco's modified Eagle's medium (OM EM) with 10% heat-inactivated fetal 
bovine serum (FBS), 20mM HEPES buffer (pH7.4), 2mM glutamine, 100U/mL 
penicillin, and 100llg/mL streptomycin. The MEFs used were generated from 
Bax/8ak knockout mouse embryos and were generously provided by Dr. Chi Li 
(University of Louisville). Hela cells were purchased through the American Type 
Tissue Collection. All cells were incubated at 37°C in 5% CO2 for culturing. 
Construct generation 
Baxa in the vector pcDNA3 was a gift from Dr. Richard Youle (National 
Institute of Health). Bax was amplified from this vector using PCR and was 
subcloned into p1RES-ne03 using EcoR1 and Not1 restriction enzymes. eGFP 
was then cloned into the N-terminal flanking region of Bax using Nhe1 and 
EcoR1 restriction enzymes to generate pIRES-eGFP-Baxa. The carboxy-
terminal tail portion (residues 166-192) of 8ax-WT was amplified from the pIRES-
eGFP-Bax construct using the following primers: 5' primer 5'- CCC CGG ATC 
CGG GAC GCC CAC GT -3' and 3' primer 5'- CCC CTC TAG ATC AGC CCA 
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TCT TCT TCC AGA TGG -3'. The amplified fragment was then cloned into 
pcDNA3-eGFP using BamH1 and Xba1 to generate pcDNA3-eGFP-Bax-tail. 
The shortened version of the WT -tail construct (residues 169-192) was 
generated using the QuikChange site-directed mutagenesis kit (Stratagene) to 
delete residues 166-169 from pcDNA3-eGFP-tail (WT). The forward 
mutagenesis primer used was 5' -GCT GTA CM GTC TGG TTC TGG ATC CAC 
GTG GCA GAC CGT GAC C -3'. The carboxy-terminal tail deleted form of Bax 
was generated by amplification from pIRES-eGFP-Baxa using the following 
primers: 5' primer 5'- GGG GGA A TT CGC CAC CAT GGA CTA CM GGA CGA 
CGA CGA CM AGA CGG GTC CGG GGA GCA -3' and 3' primer 5'- CCC CGC 
GGC CGC TCA GGG CGT CCC AM GTA G-3'. The amplified product was 
then cloned back into pIRES-eGFP-Baxa using EcoR1 and Not1 restriction 
enzymes, thereby replacing Baxa. The resulting construct was pIRES-eGFP-
BaxL1C. Amino acid substitutions for the Bax tail mutants were created using the 
QuikChange site-directed mutagenesis kit (Stratagene) according to the 
manufacturer's protocol. The template and the 5' to 3' primers used for each 
mutant are listed in Table 3. Some mutants required a two-step sequential 
mutagenesis. Each mutant was generated as a full-length Bax construct as well 
as a GFP-Bax-tail construct. The amino-terminal deleted forms of Bax were 
generated by amplification from pIRES-eGFP-Baxa (wild-type, 3xL, or 6xL) using 
the following primers: 5' primer 5'- GGG GGA ATT CGC CAC CAT GGA CTA 
CM GGA CGA CGA CGA CM AGG AGG GGA GGC ACC CGA G -3' and 3' 
primer 5'- CCC CGC GGC CGC TCA GCC CAT CTT CTT CCA G -3'. The 
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TABLE 3. 
Table 3 List of mutagenesis priners 








Bax WT 1 st round: CGCCCACGTGGCAGCTCGTGCTCATCTTTGTGGCGGG 
2nd round: GTGCTCACCGCCTCACTCCTCATCTGGMGAAGATGGGC 
Sax 3xL 1 st round: GCTCGTGCTCATCTTTGTGGCGCTAGTGCTCACCGCCTC 






V180K,L185K BaxWT 1 st round: GACCATCTTTGTGGCGGGAAAGCTCACCGCCTCACTCACCATC 
2nd round: GCGGGAAAGCTCACCGCCTCAAAGACCATCTGGAAGMGA TGGGC 
Shown are a list of the names given to the Bax tail mutants. The terJ1)late construct used for each of the mutants 
is listed as well as the 5' to 3' primer sequences used. Underlined nucleotides indicate mutated sites. 
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amplified product was then cloned back into pIRES-eGFP-Baxa using EcoR1 
and Not1 restriction enzymes, thereby replacing Baxa. The resulting constructs 
were pIRES-eGFP-Bax~N (wild-type, 3xL, or 6xL). All constructs were confirmed 
by sequencing. 
Antibodies 
Polyclonal anti-GFP (#A 11122) and polyclonal anti-PARP (214/215) 
cleavage site (#44698G) were from Invitrogen. Polyclonal anti-Calnexin (#SPA-
860) was from Stressgen. Monoclonal anti-Bax (6a7) (#556467) and monoclonal 
anti-Cytochrome c (#556433) were from BD Biosciences. Polyclonal anti-LDH-A 
(N14) (#sc-27230) and horseradish peroxidase conjugated bovine anti-goat (#sc-
2350) were from Santa Cruz. Polyclonal anti-Tom20 was produced by this 
laboratory in rabbits using GST-Tom20 as an antigen. Polyclonal anti-cleaved 
caspase-3 (Asp175) (#9661) was from Cell Signaling Technology. Horseradish 
peroxidase conjugated goat anti-rabbit (#31460) and horseradish peroxidase 
conjugated goat anti-mouse (#31430) were from Pierce. 
Confocal microscopy 
MEF (bax-/bak-) cells were grown on fibronectin-coated, 12mm round 
coverslips (Fisherbrand) within the wells of a 24-well plate. Cells were plated at 
7 x 104 cells/well for FuGENE transfection and 9 x 104 cells/well for 
LipoFectamine transfection. Transfection was done 24h later using 1 ~g 
DNAl2~L FuGENE (Roche Diagnostics) or 0.8~g DNAl2~L Lipofectamine2000 
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(Invitrogen) per well, following the protocol of the manufacturer. Indicated cells 
were treated with 10J/m2 ultraviolet (UV) light 24h after transfection. 1 h after UV 
treatment, cells were washed in PBS, fixed in fresh 4% paraformaldehyde for 
10min at RT, and permeabilized using PBS/0.1 % Triton X-1 00. Primary antibody 
incubation with the indicated antibodies (dilutions: a-Tom20 1 :200, a-calnexin 
1:1000, a-6a7 1:200) in PBS/0.1% Triton X-100/3% BSA was done for 1h at RT, 
followed by a PBS/0.1 % Triton X-100 wash. Secondary incubation was done in 
PBS/0.1% Triton X-100/3% BSA for 1h at RT using Red-Alexa 594-goat anti-
rabbit or Red Alexa 594-goat anti-mouse secondary antibody from Molecular 
Probes (dilution: 1:500). Cells were then washed with PBS/0.1% Triton X-100 
and mounted in fluorescent slide mounting medium from Oako. Fluorescence 
was analyzed under oil immersion using a 60X objective of an Olympus BX51WI 
confocal microscope. Images are presented as Z-stacks. 
Subcellular fractionation 
MEF (bax-/bak-) or Hela cells were plated in 60mm dishes at 1 x 106 
cells/dish. Transfection was done using 8f,lg DNAl20f,lL Lipofectamine2000 
according to the manufacturer's protocol. At 24 hours post-transfection, 
designated cells were treated with 8J/m2 UV light. 4h after UV treatment, cells 
were harvested by trypsinization and washed with PBS. The pelleted cells were 
brought up in 0.5mL MS buffer (210mM mannitol, 70mM sucrose, 5mM Tris, 
1mM EDTA, pH 7.5) + complete protease inhibitor (Roche Diagnostics) and 
broken with 5 back and forth strokes of a ball-bearing homogenizer as previously 
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described Balch WE, 1985. The Iysates were cleared of unbroken cells and nuclei 
with a 600rpm centrifugation step for 10min in a swing-bucket centrifuge (Sorvall 
Legend RT). Membrane was separated from cytosol by centrifugation of the 
cleared lysate for 20min at 100,000rpm in a TlA 100.2 rotor using an ultra-
centrifuge (Beckman Optimax, Beckman-Coulter). The supernatant was 
removed and saved as the cytosolic fraction. For the membrane fraction, the 
pellet was resuspended in 75/ll MS buffer + complete protease inhibitor and was 
subjected to 10 passages through a 26-gauge needle. For alkaline extraction, 
the pellet was instead resuspended in 75/ll Na2C03 (0.1 M, pH 11.5) for 30min at 
4°C with gentle agitation. The alkaline treated sample was then centrifuged as 
above in a Beckman Optimax ultra-centrifuge. The supernatant was saved as 
the alkaline-sensitive fraction. The pellet was resuspended in 75/ll MS buffer + 
complete protease inhibitor and was denoted as the alkaline-resistant fraction. 
Protein concentration was assessed using Coomassie plus Bradford protein 
assay reagent (Pierce). Ten micrograms of each protein fraction was separated 
by electrophoresis on poly-acrylamide gels, and then transferred onto PVDF 
membranes. After transfer, the membranes were incubated in blocking buffer 
(PBS/0.1 % Triton-X 100/5% milk) for 1 hr. After washing in wash buffer 
(PBS/0.1 % Triton-X 100), the membranes were incubated with the indicated 
primary antibodies in wash buffer for 1 h. The membranes were washed in wash 
buffer and then incubated in horseradish peroxidase-conjugated secondary 
antibody in wash buffer for 1 h. After the final washes in wash buffer, ECl-plus 
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reagent (Pierce) was added to the membrane and exposure to film was used to 
visualize bound antibody. 
Immunoprecipitation 
MEF (bax-/bak-) cells were plated in T75 flasks at 4 x 106 cells/flask, and 
transfected with Lipofectamine2000 using 16f.!g DNAl40f.!L Lipofectamine the 
next day. At 24h post-transfection, cells were trypsinized, and two T75 flasks 
were pooled for each construct transfected. The cells were washed with PBS 
and resuspended in 2mL MS buffer + complete protease inhibitor. The cells 
were lysed by 3 back and forth strokes with a ball-bearing homogenizer. The 
Iysates were cleared with a 15min spin at 600rpm in a swinging-bucket 
centrifuge. The resultant supernatant was separated into a membrane and 
cytosol fraction as described in the subcellular fractionation section. The 
membrane fraction was resuspended in 0.5mL CHAPS buffer (10mM HEPES, 
150mM NaCI, 1 % CHAPS, pH 7.4) + complete protease inhibitor and was 
passed 10 times through a 26-gauge needle. The cytosolic fraction was 
concentrated to 500f.!L using Amicon Ultra centrifugal filter devices (Millipore), 
and NaCI and CHAPS were added to a final concentration of 150mM and 1 %, 
respectively. One milligram of each membrane or cytosol fraction was incubated 
with 2f.!g Bax (6a7) antibody in 500f.!L total volume. Each sample was rotated for 
24h at 4 cC. Forty microliters of protein AlG Plus agarose beads (Santa Cruz) 
were then added to each sample and rotated for an additional 2h at 4 cG. The 
supernatant was removed and saved as the non-binding fraction. The beads 
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were washed 3 times with CHAPS buffer using centrifugation in an Eppendorf 
5415R microcentrifuge at 2500rpm for 1min. The beads were then resuspended 
in 50llL 1X SOS Loading Buffer (60mM Tris pH6.8, 2% SOS, 10% glycerol, 
0.02% Bromophenol Blue, 10% p-mercaptoethanol) and boiled. The beads were 
pelleted and the resulting supernatant, in addition to 20119 of protein of each 
corresponding non-binding fraction, was analyzed by Western analysis. Western 
analysis was performed as described in the subcellular fractionation section. 
Assay for apoptotic markers 
Hela cells were plated at 2 x 105 cells/well in a 12-well plate. Transfection 
was performed 24h after plating with 1.61lg ONAl41lL Lipofectamine2000. Cells 
were harvested by trypsinization at 24h post-transfection. Following the washes, 
the cells were resuspended in 751lL extraction buffer (50mM Tris, 150mM NaCI, 
0.1% Triton X-100, pH 7.4) + complete protease inhibitor and lysed by passaging 
10 times through a 26-gauge needle. The Iysates were cleared by spinning at 
13,000rpm for 15min in a Galaxy 140 microcentrifuge (VWR). Twenty 
micrograms of protein were analyzed with Western analysis as described in the 
subcellular fractionation section. Probing of PARP cleavage and caspase-3 




The Bax carboxy-terminal tail is a bona fide mitochondrial-targeting 
signal/anchor. Increasing the hydrophobicity of the sequence converts the 
Bax signal to an ER targeting signal. The function of a-helix9 within the tail of 
Bax has recently been the subject of controversy. To determine the targeting 
ability of a-helix9, the tail portion of Bax (residues166-192) was fused to the C-
terminus of GFP (Figure 12A). Confocal fluorescence was used to measure the 
localization of this construct within mouse embryonic fibroblasts lacking Bax and 
Bak (MEF bax-/bak-). In my hands it is quite clear that a-helix9 is a strong and 
specific MOM targeting signal (Figure 12B). GFP alone displays a 
diffuse/cytosolic localization (data not shown). 
To address whether the Bax tail serves a specific mitochondrial-targeting 
function, I sought to introduce mutations that would alter mitochondrial targeting. 
Initially, I explored the effect of these mutations on targeting GFP to the MOM. 
Studies from this and other laboratories have established that ER-targeted tail-
anchored proteins have relatively hydrophobic tails. In contrast, the tails of 
mitochondrially-targeted tail-anchored proteins are less hydrophobic and have 
positively charged residues flanking the transmembrane (TM) sequence Borgese N. 
2007; Horie C. 2002; Isenmann S. 1998; Wattenberg BW, 2007. Using these general properties as a 
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guide, I explored the targeting function of the Bax C-terminus. Because the Bax 
tail resembles a classic mitochondrial signal, I tested whether increasing the 
overall hydrophobicity of the Bax tail could shift targeting from the mitochondria 
to the ER. I specifically mutated polar residues within the Bax tail into 
hydrophobic leucines (Figure 12A). The 3xL tail contains three substituted 
leucines, while the 6xL tail is even more hydrophobic with six substituted 
leucines. As shown in Figure 12B, the 3xL tail co-localized with the mitochondrial 
marker. This indicates that the degree of hydrophobicity is not enough to drive 
targeting to the ER. On the other hand, the more hydrophobic 6xL tail targets 
GFP to the ER, as seen by the overlay of GFP with calnexin. These results 
confirm that the information in the Bax tail is sufficient for targeting a cytosolic 
protein to the mitochondria. Further, this mitochondrial-targeting signal can be 
switched to an ER-targeting signal by increasing the overall hydrophobicity of the 
tail. 
I then established the degree of membrane targeting and insertion of 
these constructs biochemically. The GFP-taii constructs were transfected into 
MEF (bax-/bak-) cells, and the cells were fractionated into lysate, cytosol, and 
membrane portions. The wild-type, 3xL, and 6xL tails all result in constitutive 
membrane targeting (Figure 13A). Moreover, the membrane-associated 
constructs were embedded in the membrane as assessed by resistance to 
extraction by sodium carbonate (Figure 13B). This reiterates the finding that the 
Bax tail contains all the information needed for the targeting and anchoring into 
membrane. My results contrast with those of Vallette's group, who reported that 
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the tail of Bax alone cannot target a cytosolic protein to membrane Cartron PF, 2003. 
The Bax tail used by that group was three residues shorter than the tail I have 
fused to GFP in my study. I therefore generated a GFP-fused construct with the 
exact portion of the Bax tail (residues 169-192) used in the previous studies. 
This construct localized to mitochondria as assessed by fluorescence microscopy 
(data not shown). In addition, the shortened tail was predominantly membrane 
associated (Figure 13C), although a slight increase in cytosolic localization was 
observed in comparison to the longer Bax tail in Figure 12A. 
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Figure 12. The Bax carboxy-terminus constitutes a mitochondrial-targeting 
signal that can be switched to an ER-targeting signal by increasing the 
overall hydrophobicity. (A) Site-directed mutagenesis was used to introduce 
hydrophobic residues within the Bax tail. The tails alone (residues 166-192) were 
fused to the C-terminal end of GFP. The tail sequences of wild-type Bax and the 
Bax mutants are shown. The mutated residues are shown in red. (B) The GFP-
Bax tail constructs were transfected into mouse embryonic fibroblasts lacking 
Bax and Bak (MEF bax-/bak-). Confocal microscopy was then used to visualize 
the localization of these constructs. An anti-Tom20 antibody and an anti-calnexin 
antibody were used as a mitochondrial and ER markers, respectively. 
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Figure 13. The signals in the wild-type and mutated Bax tails result in 
membrane targeting and insertion of GFP. (A) The GFP-Sax tail constructs 
were transfected into MEF (bax-/bak-) cells as in Figure 12. Subcellular 
fractionation was used to isolate lysate, membrane, and cytosol fractions from 
these cells. Western analysis was then used to analyze the localization of the 
Sax tail constructs within these fractions. Tom20 and lactate dehydrogenase 
(LDH) were used as a membrane marker and cytosolic marker, respectively. L-
lysate, M-membrane, C-cytosol. (B) Membrane fractions from (A) were 
treated with 0.1 M Na2C03 (pH 11.5) and separated into pelletable and 
supernatant fractions to test for stable membrane insertion. Appearance of the 
construct in the pellet fraction indicates stable membrane insertion. Tom20 
(membrane inserted) and cytochrome c (soluble) were used as controls. Att-
attached, Ins-inserted. (C) A shorter version of the wild-type Sax tail containing 
residues 169-192, previously examined by Cartron et ai, was tested for its ability 
to target a passenger protein to membrane fractions. Subcellular fractionation 
and Western analysis were used as in (A). 
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The targeting signal in the Bax tail does not play the primary 
mitochondrial-addressing role in full-length Bax. Having confirmed that the 
Bax tail can specifically target a cytosolic passenger protein to the mitochondria, I 
tested this targeting function within the context of full-length Bax. GFP was fused 
to the N-terminus of full-length Bax (Figure 14A), and the localization of this 
construct was assessed using confocal microscopy. Previous studies have 
shown that fused GFP has no effect on the function of Bax Schinzel A, 2004; Nechushtan A, 
1999; Wolter KG, 1997. Under normal conditions, Bax exhibits a diffuse pattern in the 
cytosol (Figure 14B). Using ultraviolet light (UV) treatment as an apoptotic 
inducer, Bax then translocated to the mitochondria. This is shown by the co-
localization with the mitochondrial marker Tom20. The same 3xL and 6xL tail 
mutations depicted in Figure 12A were then introduced into the full-length Bax 
construct to determine if this could shift targeting of Bax from the mitochondria to 
the ER (Figure 14A). As expected, the 3xL mutant resulted in mitochondrial 
targeting (Figure 14B). Surprisingly, the 6xL mutant also displayed mitochondrial 
targeting, in contrast to the ER-targeting exhibited with the 6xL tail fused to GFP 
as depicted in Figure 12B. Because Bax6xL localized to the mitochondria 
despite the ER-targeting signal within the tail, this suggests that the targeting of 
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Figure 14. Increasing the hydrophobicity of the Bax signal/anchor in the 
context of full~length Bax does not alter Bax mitochondrial targeting. (A) 
Mutations increasing the hydrophobicity of the Bax signal/anchor, corresponding 
to those depicted in Figures 12 and 13, were introduced into a full-length Bax 
construct. GFP was fused to the amino-terminus of this construct. The tail 
sequences of wild-type Bax and the Bax mutants are shown. The mutated 
residues are shown in red. (B) The GFP-fused Bax constructs were transfected 
into MEF (bax-/bak-) cells. Wild-type transfected cells were subjected to UV 
treatment as described in materials and methods. Confocal microscopy was then 
used to visualize the localization of these constructs. An anti-Tom20 antibody 
was used as a mitochondrial marker. 
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Deletion of the N-terminal a-helix1 of Sax disrupts mitochondrial 
targeting and results in constitutive ER-targeting. Vallette's group has 
identified a potential mitochondrial-addressing signal within the N-terminal Q-
helix1 of Bax Cartron PF, 2003; Cartron PF, 2005; Belio! G, 2007. This finding is in accordance 
with my results that indicate that the Bax C-terminal tail is not the primary 
addressing signal for Bax mitochondrial targeting. Thus, I wanted to inv~stigate 
the requirement of the Bax N-terminal domain for mitochondrial-targeting. I also 
wanted to determine if the Bax tail could control Bax targeting in the absence of 
the N-terminus. I therefore deleted the entire N-terminus (6.N) containing Q-
helix1 (residues 1-37) from wild-type Bax, as well as the 3xL and 6xL Bax tail 
mutants (Figure 15A). Localization of the GFP-fused Bax6.N constructs was 
visualized in MEF (bax-/bak-) cells by confocal microscopy. As shown in Figure 
15B, deletion of the N-terminal domain of Bax inhibits mitochondrial targeting and 
results in predominantly ER targeting regardless of the signal within the tail. This 
indicates that the N-terminal domain is required for correct mitochondrial 
targeting, and that the Bax tail does not function as a targeting signal even in the 
absence of the N-terminal domain. 
I also determined the degree of membrane targeting and insertion of these 
constructs biochemically. Each Bax6.N construct was transfected into MEF (bax-
/bak-) cells. The transfected cells were then fractionated into lysate, membrane, 
and cytosol fractions. Deletion of the N-terminus of Bax wild-type, 3xL, and 6xL 
results in constitutive membrane targeting of each construct (Figure 16A). 
Moreover, each of these Bax6.N constructs is inserted within the membrane, as 
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assessed by alkaline resistance (Figure 16B). These results suggest that 
deletion of the N-terminal domain disrupts the regulation of Bax that keeps it in 
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Figure 15. Deletion of the N-terminal a-helix1 of Bax results in a shift from 
mitochondrial targeting to ER-targeting of Bax. (A) The amino-terminal 
residues 1-37, including a-helix1, were deleted from the full-length wild-type, 3xL, 
and 6xL Sax constructs. These proteins were expressed as GFP-fusion proteins 
where GFP was fused to the N-terminus of each Sax construct. (B) The GFP-
fused SaxflN constructs were transfected into MEF (bax-/bak-) cells. Confocal 
microscopy was then used to visualize the localization of these constructs. An 
anti-Tom20 antibody and an anti-calnexin antibody were used as a mitochondrial 
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Figure 16. Deletion of the N-terminal a-helix1 of Bax results in constitutive 
membrane targeting and insertion of full-length Bax. (A) The GFP-fused, full-
length BaxLlN constructs used in Figure 15 were tested. These constructs were 
transfected into MEF (bax-/bak-). Subcellular fractionation was performed in 
order to obtain lysate, membrane, and cytosol fractions. Localization of the Bax 
constructs within these fractions was determined using Western analysis. L-
lysate, M-membrane, C-cytosol. (B) Membrane fractions from the MEF (bax-
/bak-) cells from (A) were treated with 0.1 M Na2C03 (pH 11.5) to observe 
insertion properties of the Bax mutant constructs as described in Figure 13B. 
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The Bax tail plays a role in regulating the membrane targeting of Bax 
and the change into an open/active conformation of Bax. Some studies 
have indicated that the Bax tail functions as a regulator of Bax activation Suzuki M, 
2000; Arokium H, 2004. As shown in Figure 14B, the 3xL and 6xL full-length Bax 
mutants constitutively target to the mitochondria in the absence of an apoptotic 
inducer. Subcellular fractionation of 3xL and 6xL transfected cells displays a 
constitutive membrane distribution of these mutants in both MEF (bax-/bak-) and 
Hela cells (Figure 17 A), in agreement with the confocal microscopy results. For 
reasons that are not clear, somewhat more cytosolic Bax is observed in Hela 
cells than in MEF cells. Alkaline extraction shows that the 3xL and 6xL Bax 
mutants are integrated into the membrane (Figure 17B). Conversely, wild-type 
Bax is found predominantly in the cytosolic fraction (Figure 17 A). These results 
indicate that the mutations made within the tail disrupt a negative regulatory 
effect that the tail has on Bax targeting. 
To further investigate this effect, I therefore assessed the conformational 
state of these Bax constructs. Previous results have demonstrated that Bax is in 
a closed conformation when inactive, and when activated Bax changes into a 
more open conformation, exposing a targeting signal. I wanted to determine if 
the 3xL and 6xL mutations result in an open/active conformation of Bax, thereby 
allowing for constitutive targeting. GFP-fused full-length wild-type, 3xL, and 6xL 
Bax were transfected into MEF (bax-/bak-) cells. A Bax antibody (6a7) that 
specifically recognizes Bax in the open/active conformation was used to evaluate 
the conformation of these constructs Hsu YT, 1998; Hsu YT, 1997; Yethon JA, 2003 
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confirmed, by confocal microscopy, that wild-type Sax is not recognized by the 
6a7 antibody unless it is treated with UV (Figure 18A). Conversely, the 3xL and 
6xL Sax mutants are in an open/active conformation in the absence of UV 
treatment, as probed by staining with the 6a7 antibody. I then tested whether 
this conformational change is a stable property induced by these mutations, or is 
a result of membrane binding. Cytosol and membrane fractions were prepared 
from transfected cells and immunoprecipitated with the 6a7 antibody. The 
immunoprecipitates were then analyzed by immunoblotting to GFP. Although the 
3xL and 6xL mutants are predominantly in the membrane fraction, a small 
amount of these proteins are found within the cytosol and can be measured 
using this method. Wild-type Sax does not immunoprecipitate with the 6a7 
antibody and is found in the non-binding fraction as expected (Figure 18S). 3xL 
and 6xL solubilized from the membrane fractions are immunoprecipitated with 
6a7, in agreement with the confocal microscopy results. Cytosolic 6xL is 
immunoprecipitated from the cytosolic fraction. This illustrates that the 6xL 
mutation leads to the conformational activation of Sax directly and independently 
of membrane integration. In contrast, the cytosolic 3xL mutant was not 6a7 
reactive. This may indicate that the activation of Sax by the 3xL mutation is more 
transient than that induced by 6xL. 
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Figure 17. Mutations that increase the hydrophobicity of the 8ax 
tail/anchor result in constitutive membrane targeting and insertion of full-
length 8ax (A) The GFP-fused, full-length Bax constructs used in Figure 14 
were tested. These constructs were transfected into MEF (bax-/bak-) cells and 
Hela cells. Subcellular fractionation was performed in order to obtain lysate, 
membrane, and cytosol fractions. Localization of the Bax constructs within these 
fractions was determined using Western analysis. L-Iysate, M-membrane, C-
cytosol. (8) Membrane fractions from the MEF (bax-/bak-) cells from (A) were 
treated with 0.1 M Na2C03 (pH 11.5) to observe insertion properties of the Bax 
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Figure 18. The mutations made in the Bax tail result in an active 
conformation of Bax. (A) The GFP-fused Bax constructs were transfected into 
MEF (bax-/bak-) cells. Wild-type transfected cells were subjected to UV 
treatment as described in materials and methods. Bax (6a?) antibody was used 
to specifically detect Bax in an active conformation. Confocal microscopy was 
used to visualize binding of the 6a? antibody. (B) Immunoprecipitation (IP) with 
the Bax (6a?) antibody was used to pull-down GFP-fused WT, 3xL, or 6xL Bax 
that was in the active conformation. The IPs were performed on either cytosolic 
or membrane subcellular fractions. Probing for WT in the cytosol was used as a 
negative control. The IP samples, as well as the non-binding fractions, were then 




Deletion of the Bax tail results in an open/active conformation of 
Bax, yet Bax cannot target to the mitochondria without the tail. Studies by 
various groups have produced contradictory findings on the requirement of the 
Bax tail for Bax targeting and activity. My results indicate that the Bax tail is not 
the primary targeting signal for mitochondrial targeting, yet the tail plays an 
important role in the regulation of Bax conformational change and targeting. 
Therefore, I deleted the Bax tail to test whether this domain is dispensible for Bax 
activation and targeting. The deletion mutant (Bax~C) was generated by 
removing residues 169-192, which includes a-helix9 and its flanking residues, 
from GFP-fused full-length Bax (Figure 19A). To determine the effect of this 
deletion on the conformational state of Bax, I used the Bax 6a7 antibody specific 
for the active conformation of Bax. BaxL1C was transfected into MEF (bax-/bak-) 
cells, and confocal microscopy was used to analyze Bax 6a7 binding with or 
without UV treatment. The deletion of the Bax tail resulted in an open/active 
conformation of Bax independent of an apoptotic inducer as measured by 6a7 
reactivity (Figure 19B). This result supports my findings with the 3xL and 6xL tail 
mutants that the tail is an important negative regulator of Bax activation, 
specifically by maintaining Bax in a closed/inactive conformational state. 
Because BaxL1C is in an open/active conformation, it would be expected that 
BaxL1C would constitutively target to the mitochondria, as seen with 3xL and 6xL. 
Therefore, BaxL1C was transfected into MEF (bax-/bak-) cells, and localization of 
this construct was assessed by confocal fluorescence with or without UV 
treatment. Surprisingly, despite the fact that Bax~C is in an active conformation, 
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this construct remains predominantly in the cytosol even upon apoptotic induction 
by UV treatment (Figure 20A). Subcellular fractionation of BaxLiC-transfected 
Hela cells reinforces these results. As previously observed, wild-type Bax 
becomes membrane localized after UV treatment, yet BaxLiC remains in the 
cytosol (Figure 20B). Therefore, while the Bax tail does not dominate the 
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Figure 19. Deletion of the Bax tail results in an active conformation of Bax. 
(A) A tail-deleted form of Sax (~C) was generated by deletion of residues 169-
192. The ~C mutant was fused to the C-terminus of GFP. (B) The GFP-fused 
Sax~C construct was transfected into MEF (bax-/bak-) cells. The Sax (6a7) 
antibody was used to specifically detect Sax in an active conformation. Confocal 
microscopy was used to visualize binding of the 6a7 antibody in the absence or 
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Figure 20. Deletion of the Bax tail results in a cytosolic distribution 
independent of apoptotic stimulus. (A) The GFP-fused Bax~C construct was 
transfected into MEF (bax-/bak-) cells. Confocal microscopy was then used to 
visualize the localization of this construct. An anti-Tom20 antibody was used as a 
mitochondrial marker. (B) BaxWT and Bax~C were transfected into Hela cells 
and were either treated or not treated with UV light. Subcellular fractionation was 
performed to obtain lysate, membrane, and cytosol fractions. Localization of the 
Bax constructs within these fractions was determined using Western analysis. 
L-Iysate, M-membrane, C-cytosol. 
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FIGURE 21. 
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The constitutively-targeted 3xL and 6xL Bax mutants exhibit 
enhanced apoptotic-inducing ability in comparison to wild-type and AC 
Bax. Bax 3xL, 6xL, and I1C mutants are all in an open/active conformation. 
However, while 3xL and 6xL are constitutively mitochondrial-targeted, Baxl1C is 
constitutively cytosolic. This prompted us to evaluate the subsequent apoptotic-
inducing ability of these Sax mutants in the absence of an apoptotic stimulus in 
Hela cells. These cells produce more robust apoptotic signals than the MEF 
cells used in the experiments depicted above. Sax wild-type, 3xL, 6xL, and I1C 
were transfected into Hela cells along with empty vector as a negative control, 
and apoptosis was measured without addition of an apoptotic inducer. PARP 
cleavage and caspase-3 cleavage were used to measure apoptosis. As shown 
in Figure 21, wild-type Sax and Baxl1C do not stimulate apoptosis and are 
comparable to vector alone. Conversely, 3xL and 6xL show clear induction of 
apoptosis in the absence of an external apoptotic stimulus, as measured by 
PARP and caspase-3 cleavage. 
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Figure 21. In the absence of apoptotic stimulus, the constitutively-targeted 
3xL and 6xL mutants of Bax exhibit enhanced apoptosis in comparison to 
BaxWT and BaxflC. GFP-fused Sax constructs were transfected into Hela cells 
for 24 hours. Lysates from these cells were then subjected to Western analysis. 
An antibody that specifically recognizes cleaved PARP and an antibody that 
specifically recognizes cleaved caspase-3 were used as a measure of apoptosis. 
LDH was used as a loading control. EV-empty vector 
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Inhibiting insertion of the Bax tail disrupts Bax mitochondrial~ 
targeting. My results have revealed that the Bax tail does not play the 
addressing role in Bax mitochondrial targeting. However, I have shown that the 
tail is indispensable for Bax targeting. This led us to investigate whether the 
membrane-insertion property of the Bax tail is important for Bax mitochondrial 
translocation. Selected residues within the Bax hydrophobic transmembrane 
domain of the tail were replaced with charged residues in order to inhibit insertion 
of the tail into the membrane (Figure 22A). Residues G179 and T186 were 
chosen due to their location in the middle and end of the transmembrane 
segment, respectively. S184 was chosen because previous studies have 
identified this residue as having effects on Bax mitochondrial targeting Nechushtan A, 
1999; Gardai SJ, 2004; Xin M, 2005. V180 and L 185 were chosen in order to replace 
hydrophobic residues of the transmembrane sequence rather than polar 
residues. Initially, the tails in the context of GFP as a passenger protein were 
assessed by microscopy to confirm that these sequence changes disrupt the 
membrane insertion of the tail sequence (Figure 22B, first column). GFP was 
fused to the N-terminus of each of the mutant tails. The GFP-taii constructs were 
transfected into MEF (bax-/bak-) cells, and localization was visualized using 
confocal microscopy. Introducing a single charged residue at serine 184 (S184K, 
S1840, S184E) or substituting two charged residues for hydrophobic residues 
(V180K,L 185K) resulted in a diffuse, cytosolic distribution. This contrasts sharply 
with the distinct mitochondrial targeting of GFP fused to the wild-type and 3xL 
sequence or the endoplasmic reticulum targeting of the 6xL sequence (Figure 
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12). However, T186K and G179K tails only partially inhibited the targeting of 
GFP to mitochondria. Although a portion of these latter constructs is localized to 
the mitochondria, a significant amount is diffuse throughout the cell. 
The effects of these same mutations were then investigated in the context 
of full-length Bax. GFP was fused to the N-terminus of the full-length Bax 
mutants. These constructs were transfected into MEF (bax-/bak-) cells. 
Transfected cells were then subjected to analysis using confocal microscopy and 
subcellular fractionation. The introduction of charged residues within the Bax tail 
resulted in an open/active conformation of Bax, as detected by 6a7 reactivity 
(Figure 22B). However, even in the active conformation, Bax is not able to target 
to the mitochondria with a mutated tail that cannot insert. All of the mutants 
display a cytosolic distribution (Figures 22B and 22C). This is in contrast to Bax 
3xL and 6xL mutants that are in the active conformation, yet constitutively target 
to the mitochondria (Figures 14 and 17, Table 2). These results indicate that 
inhibiting the ability of the tail sequence to insert into membranes disrupts 
mitochondrial targeting of Bax. 
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Full-length constructs 
6a7 GFP Tom20 overlay 
Figure 22. Inhibiting insertion of the Bax tail by introducing charged 
residues disrupts Bax mitochondrial-targeting. (A) Site-directed mutagenesis 
was used to introduce charged residues within the Bax tail. These mutations 
were made in both GFP-tagged full-length Bax as well as GFP fused to the tails 
alone (residues 166-192). The tail sequences of wild-type Bax and the 8ax 
mutants are shown. The mutated residues are shown in red. (B) The GFP-taii 
and GFP-Bax (full-length) constructs were transfected into MEF (bax-/bak-) cells. 
Confocal microscopy was then used to visualize the localization of these 
constructs. An anti-Tom20 antibody and an anti-calnexin antibody were used as 
a mitochondrial and ER marker, respectively. 8ax 6a7 antibody was used to 
detect the open/active conformation of full-length 8ax constructs. (C) The GFP-
fused, full-length 8ax mutants used in (8) were tested. These constructs were 
transfected into MEF (bax-/bak-) cells. Subcellular fractionation was performed in 
order to obtain lysate, membrane, and cytosol fractions. Localization of the 8ax 
constructs within these fractions was determined using Western analysis. L-
lysate, M-membrane, C-cytosol. 
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TABLE 4. 



































Shown are a list of the names given to Bax wr and the Bax mutants. An open/active conformation is 




In these studies, I first show that the carboxy-terminal tail of Bax can serve 
as a bona-fide mitochondrial-targeting signal/anchor. Surprisingly, despite this 
property I demonstrate that the Sax tail does not play the primary role in 
addressing of full-length Bax to the mitochondria. However, I show that the Bax 
tail does play an important negative regulatory role in Bax activation of targeting. 
Deletion of the Sax tail results in an open/active conformation, yet Sax cannot 
localize to the mitochondria without the Sax tail. This indicates a requirement of 
the Sax tail for Sax mitochondrial translocation. Sy making mutations within the 
Sax tail that inhibit insertion of this domain, I illustrate that the membrane 
insertion of the Bax tail is crucial for Sax mitochondrial targeting. 
Studies on Sax have yielded conflicting results as to whether the Sax tail 
functions as a targeting signal that is necessary for Sax mitochondrial 
translocation. There have been reports that the Bax tail cannot target a fused 
cytosolic passenger protein to the mitochondrial membrane, suggesting that the 
Sax tail does not contain a mitochondrial-targeting signal Cartron PF, 2003; Nechushtan A, 
1999. Vallette's group has also presented findings in which the deletion of the Sax 
tail has no effect on mitochondrial targeting or apoptotic inducing ability in 
comparison to wild-type Sax, indicating that the Sax tail is 
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dispensible for targeting and Bax activation Cartran PF, 2005; Cartran PF, 2003; Tremblais K, 
1999. In addition, they have identified a potential targeting signal within the N-
terminal a-helix1 of Bax that directly interacts with the MOM receptor Tom22. 
On the other hand, several other groups have presented results that 
indicate a mitochondrial-targeting function of the Bax tail. Studies have shown 
that the Bax tail itself contains sufficient mitochondrial-targeting and anchoring 
information when fused to a cytosolic passenger protein Gaping IS, 1998; Schinzel A 2004. 
Deletion of the Bax tail can prevent targeting of full-length Bax to the 
mitochondria as well as inhibit the apoptotic inducing ability of Bax Schinzel A, 2004; 
Wolter KG, 1997; Nechushtan A, 1999. Nechushtan et al showed that even deletion of the 
last 5 amino acids from the Bax tail can inhibit targeting. In the same study, they 
demonstrated that various point mutations at residue S184 in the Bax tail either 
increased or inhibited Bax mitochondrial targeting, further indicating an important 
targeting role of the Bax tail. These localization and functional studies have 
established that the Bax carboxy-terminus serves a role identical to that of 
homologous sequences in other "tail-anchored" proteins, in which the carboxy 
terminus serves as both the addressing signal and membrane anchor Wolter KG, 
1997; Gaping IS, 1998; Hsu YT, 1998; Nguyen M, 1993 
In my hands, it is clear that the Bax tail itself can serve as a mitochondrial-
targeting signal and can direct a cytosolic passenger protein specifically to the 
mitochondria. Moreover, the behavior of the 6xL mutation demonstrates that the 
tail obeys the sequence rules that determine whether tail-anchors direct proteins 
to the mitochondria versus the endoplasmic reticulum. The varying lengths of the 
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Bax tail used in previous studies may account for the differences in results. 
Vallette's group used residues 169-192. In contrast, I used residues 166-192 of 
the Bax tail, which contains the entire transmembrane domain in addition to the 
N-terminal and C-terminal flanking residues. Studies of targeting requirements 
for tail-anchored proteins have demonstrated that the residues flanking the 
hydrophobic portion of the membrane anchor are essential for targeting Isenmann 8, 
1998; Kaufmann T, 2003; Masaki R, 2003; Kim PK, 1997. Shorter portions of the Bax tail may not 
contain all of the essential residues for correct mitochondrial targeting, resulting 
in cytosolic localization. Using a shorter Bax tail segment (residues 169-192) 
that was used by Vallette's group, I show that although this shorter version can 
still target to the mitochondria to some extent, the efficiency is lower than the 
longer version (Figure 13C). 
However, my results are in agreement with the notion of the mitochondrial-
targeting signal of Bax residing in the N-terminal a-helix1 and not in the Bax tail 
Cartron PF, 2003. I demonstrate that replacing the C-terminal tail of Bax with an ER-
targeting signal (6xL) has no effect on targeting of full-length Bax. This indicates 
that another targeting-signal exists in the structure of Bax that overrides the 
targeting signal within the tail, refuting the idea that the tail is the primary 
targeting signal within Bax. In accordance with this, when I deleted the Bax N-
terminal domain including a-helix1, mitochondrial-targeting of Bax was abolished. 
Instead, BaxflN localized predominantly to the ER. Additionally, translocation to 
the ER was observed independently of the targeting signal within the tail. This is 
consistent with the results of Vallette's group that indicate that the primary 
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mitochondrial-targeting signal is within the N-terminal a-helix1 domain. It is not 
clear why the N-terminal deleted form of Sax targets to the ER. Localization of 
wild-type Sax to the ER is not widely studied at this point. Therefore, little is 
known about the mechanism of Sax targeting to this organelle. It is possible that 
there is another targeting signal within the Sax structure that allows for targeting 
to the ER. 
While the Sax tail does not serve as a targeting sequence, I find that it is 
absolutely required for Sax localization to the mitochondria. What then is its 
function? My results suggest that the Sax tail tethers Sax to the mitochondrial 
membrane subsequent to or in conjunction with a targeting interaction mediated 
by sequences elsewhere in the protein. I come to this conclusion based on my 
observation that disrupting the ability of the tail sequence to insert into 
membranes blocks Sax mitochondrial localization. This finding provides a 
possible explanation for the necessity of the Sax tail for targeting, and is 
consistent with the results obtained when the Sax tail is deleted and 
mitochondrial targeting is inhibited. Interestingly, previous studies have shown 
that Sax mitochondrial translocation can be inhibited by phosphorylation of the 
tail residue 8184 Gardai SJ, 2004; Xin M, 2005 My results suggest that this 
phoshorylation prevents the required membrane insertion of the tail, thereby 
inhibiting Sax targeting. My data using the phosporylation-mimicking residues D 
and E at residue 8184 are consistent with this notion. I cannot rule out that the 
introduction of charged residues within the tail does not have additional effects 
on the Sax protein. The inhibition of mitochondrial targeting that is observed with 
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these tail mutants could also be due, in part, to disruption or promotion of Bax 
interaction with other proteins. It is also unclear why Vallette's group has 
described the Bax tail as being dispensible for Bax mitochondrial-targeting. 
Expression level differences or cell-type differences could result in suitable 
conditions for stable association of the tail-deleted form of Bax with the 
mitochondria, accounting for these discrepancies. 
The Bax tail also appears to function as a negative regulator of Bax 
activation Suzuki M, 2000; Arokium H, 2004. The C-terminal tail of Bax is tucked into a 
hydrophobic pocket in the structure of Bax, covering the BH3 domain and a-
helices 5 and 6. The tail is retained in the pocket by hydrophobic interactions 
and hydrogen bonding Suzuki M, 2000. Replacement of the Bax tail with the C-
terminal tail of either BcI-2 or BcI-xL results in constitutive mitochondrial targeting 
of Bax Goping IS, 1998; Suzuki M, 2000; Tremblais K, 1999. Whereas the conserved sequence of 
the Bax tail allows for a tight fit into the hydrophobic pocket, the imperfect fit of 
the alternative tails into the hydrophobic groove allows for an open/active 
conformation of Bax. This would result in the constitutive exposure of the tail 
sequence and the activation of Bax. My results have demonstrated a 
comparable phenomenon, where mutations within the Bax tail result in an 
open/active conformation of Bax, constitutive mitochondrial targeting, and 
enhanced apoptotic-inducing ability. Moreover, mutation of six residues within 
the tail, rather than three, had a greater effect on Bax conformation, reiterating 
the idea that increased disruption of the interactions between the tail and the 
hydrophobic groove results in dissocation of the Bax tail. The complete deletion 
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of the tail also results in an open conformation of Sax, illustrating that the specific 
positioning of the tail within the hydrophobic pocket is important in maintaining 
Bax in a closed/inactive conformation. This negative regulatory role of the Bax 
tail is comparable to that of the ART (apoptotic regulation of targeting) domain in 
the N-terminal portion of Bax Goping IS, 1998; Cartron PF, 2005; Cartron PF, 2003. 
Taken together, my findings have presented possible explanations for the 
conflicting results describing the function of the Bax tail. My results support 
previous findings that the Bax tail serves as a negative regulator of the initial 
conformational change that leads to Bax mitochondrial translocation. While my 
data contradict the notion that the Bax tail serves as the primary targeting signal 
for mitochondrial targeting, I suggest an important anchoring/tethering role of the 
Bax tail that is required for mitochondrial targeting of Bax. I propose a model 
where after the initial addressing of Sax to the MOM, the Bax tail functions to 
stabilize Bax at the membrane (Figure 23). This would then allow for complete 
integration of Bax into the membrane where helices 5 and 6 can be inserted. 
Consistent with this model, Andrews and colleagues also suggest a stepwise 
process of transient to stable interaction of Bax with the membrane Yethon JA, 2003; 
Leber B, 2007. Further studies will be needed to elucidate greater detail of this 
insertion process. 
It is well accepted that translocation of Bax to the mitochondria is essential 
for Bax-induced apoptosis. The numerous studies on Bax have uncovered 
various mechanisms involved in Bax activation and mitochondrial translocation. I 
believe that Bax activation and translocation are achieved through a stepwise 
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process that consists of these various mechanisms that have been identified. 
Bax is retained in an inactive state in the cytosol due to a specific conformation of 
Bax. The N-terminal ART sequence and the carboxy-terminal tail of Bax serve to 
keep Bax in an inactive/closed conformation. By sitting in the hydrophobic 
groove, the Bax tail also functions to cover the Bax BH3 domain that can interact 
with activating proteins such as tBid. Inhibitory proteins, such as 14-3-3 and 
Ku70, can also bind to Bax and maintain Bax in an inactive conformation. 
Interactions with the inhibitory proteins must be disrupted and Bax must 
undergo a conformational change before it can translocate to the mitochondrial 
outer membrane (MOM). It is unclear what triggers this conformational change 
of Bax, though addition of cytosolic extract stimulates translocation of 
recombinant Bax. Therefore, it is likely that activating proteins are involved. 
These proteins may induce a conformational change by competing with the Bax 
tail for the BH3 domain in the hydrophobic pocket. The best described example 
of a Bax activating protein is the BcI-2 BH3-only protein, Bid. The truncated form 
of Bid, tBid, induces Bax conformational change and mitochondrial translocation. 
tBid has been shown to interact with the BH3 domain of Sax, hence this 
interaction could facilitate release of the Bax tail and the subsequent activating 
conformational change. In addition, other factors may serve as indirect activators 
by blocking the inhibitory actions of the inhibitory proteins. This is exemplified by 
the action of the BH3-only proteins that block the Bax-inhibitory proteins BcI-2 
and Bcl-xL. 
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I believe that the conformational change of Bax allows for exposure of a 
mitochondrial signal, possibly a-helix1 of the Bax N-terminus. This 
mitochondrial-targeting signal interacts loosely with a factor at the surface of the 
mitochondria and does not insert into the MOM. The interaction of the Bax 
mitochondrial-targeting signal with the mitochondria is transient until the Bax C-
terminal tail inserts into the membrane. Insertion of the Bax tail is essential for 
tethering of Bax to the mitochondrial membrane. The insertion of the Bax tail 
then stabilizes Bax for complete integration of Bax a-helices 5 and 6 into the 
MOM. Once the Bax tail is inserted, I believe that the subsequent integration of 
a-helices 5 and 6 occurs rapidly. 
This proposes a complex model that involves a stepwise process of Bax 
activation. This sequential activation allows for a tight regulation of Bax due to 
the number of steps that are required for complete activation. Tight control is 
vital to keep Bax from aberrantly being activated, since Bax is such a potent 
stimulus of cell death. Future studies need to focus on verifying each step. 
However, it is difficult to isolate intermediate steps in order to show it is in a 
stepwise fashion. Identifying all of the steps of Bax activation will provide more 





















Figure 23. Model of Bax targeting to the mitochondria. Sax is found in a 
closed/inactive state in the cytosol. The correct orientation of the tail in the 
hydrophobic pocket keeps Sax in a closed/inactive conformation. 1) An apoptotic 
trigger induces a conformational change into an open conformation of Sax, 
thereby exposing a mitochondrial-addressing signal. 2) The exposed addressing 
signal interacts with the mitochondrial membrane in a loose fashion whereby Sax 
can attach and detach from the membrane. 3) The Sax tail must insert into the 
MOM, tethering Sax to the membrane and 4) allowing for complete integration of 




A PEPTIDE DERIVED FROM A MITOCHONDRIAL TAIL-ANCHOR SHOWS 
AN INCREASED PROPENSITY FOR HELIX FORMATION AS COMPARED 
TO A PEPTIDE DERIVED FROM AN ER-DIRECTED SEQUENCE 
Introduction 
Tail-anchored proteins consist of an N-terminal cytosolic globular domain 
that is tethered to an intracellular membrane by a C-terminal hydrophobic 
transmembrane domain or tail-anchor Wattenberg BW, 2001; Borgese N, 2003; Habib SJ, 2003; , 
Borgese N, 2003. The C-terminal transmembrane domain serves as the addressing 
signal as well as the anchor that tethers the protein to the correct membrane 
Wattenberg BW, 2001; Habib SJ, 2003; Borgese N, 2003. Because the C-terminal sequence is the 
final portion of the protein to exit the ribosome during translation, targeting to the 
destination membrane is post-translational. Tail-anchored proteins localize 
initially to the endoplasmic reticulum or the mitochondria, and to a lesser extent 
at peroxisomal membranes Borgese N, 2003. The targeting signal within the C-
terminal tail that differentiates between membranes does not consist of specific 
amino acid sequences. Instead, distinctive structural characteristics of the tail 
allow for differential targeting (Table 2). These characteristics include 
hydrophobicity, polarity, charged flanking-residues, and spacing of residues 
Borgese N, 2001; Horie C, 2002; Isenmann S, 1998; Habib SJ, 2003 ER-targeted tail-anchored 
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proteins contain relatively hydrophobic transmembrane sequences. Alternatively, 
mitochondrial-targeted tail-anchored proteins contain less hydrophobic 
transmembrane domains due to the presence of polar residues or due to 
containing shorter transmembrane segments. The mitochondrial-targeting tail 
anchors also contain positively-charged residues that flank the transmembrane 
sequence. A relevant example of these properties can be described with two 
splice isoforms, A and B, of the tail-anchored protein VAMP1 Isenmann S, 1998. 
VAMP1A targets specifically to the ER. The tail anchor of VAMP1 B differs from 
the tail anchor of VAMP1A only by shortening of the hydrophobic transmembrane 
domain and the addition of positively charged residues at the end of the tail-
anchor sequence. These slight changes allow for targeting of VAMP1 B 
specifically to the mitochondria. Although these general structural characteristics 
have been established, the mechanism by which these differing structures 
selectively target to destination membranes is poorly understood. To shed more 
light on the differences in biophysical properties of mitochondrial- versus ER-
targeted tail anchors, I investigated differences in secondary structure formation 
of representative artificial tail-anchor sequences. 
Materials and Methods 
Circular dichroism of tail-anchor peptides 
The following synthetic peptides (Invitrogen) were examined by circular 
dichroism: MOA-tail (KSGSGSRIIGFSTSVTALGFVLYRYRLLPRS) and L16 
(KSGSGSRLLLLLLLLLLLLLLLLRYRLLPRS). Differing concentrations of 
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trifluoroethanol (TFE) or dodecylphosphocholine (OPC; Avanti Polar Lipids) in 
10mM phosphate buffer, or 4mM SOS in 5mM Tris pH 7.6 were used to solubilize 
the peptides. Peptide concentrations were determined using absorbance 
readings at a wavelength of 220. Concentrations corresponding to an 
absorbance reading of 0.7-0.8 were found to be optimal for CO readings. 
Spectra were collected on a Jasco J-800 spectropolarimeter equipped with a 
thermoeclectric temperature control unit. Parameters for the CD analysis are as 
follows: temperature-20°C, sensitivity-standard (100mdeg), start-260nm, 
end-178nm, data pitch-0.2nm, scan mode-continuous, scan speed-
50nm/min, response-2s, bandwidth-1 nm, accumulation-10. The spectra 
resulting from the CD analysis were analyzed using CONTINLL software to 
determine the percent of helical conformation Provencher SW, 1981. 
Results and Discussion 
Tail-anchors direct targeting based on distinct structural characteristics 
rather than specific sequence requirements. By measuring the formation of 
secondary structure, I determined differing biophysical properties of a 
mitochondrial- versus an ER-targeted tail-anchor peptide. The mitochondrial-
targeted tail-anchor peptide was derived using sequence from the tail-anchor of 
the mitochondrially-targeted protein monoamine oxidase: 
KSGSGSRIIGFSTSVTALGFVLYRYRLLPRS. A poly-leucine sequence was 
used to represent an ER-targeted tail-anchor peptide, based on the high 
hydrophobicity characteristics of ER-targeted tail-anchors. This poly-leucine 
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sequence was substituted into the tail-anchor sequence of monoamine oxidase: 
KSGSGSRLLLLLLLLLLLLLLLLRYRLLPRS. Both of these sequences were 
confirmed to target to the specified membrane (Table 2). Two conditions were 
used to measure the propensity of these peptides to form secondary structure. 
First, I wanted to test increasing concentrations of trifluoroethanol (TFE), a 
solvent that promotes helix formation. Secondly, dodecyl phosphocholine (DPC) 
was used as a membrane-mimetic zwitterionic detergent. 
Peptides were first dissolved in aqueous buffer containing increasing 
concentrations of TFE. Circular dichroism was used to determine secondary 
structure at the various concentrations. Figure 24A shows the delta epsilon 
measurements versus wavelength for the mitochondrial tail-anchor peptide, 
MOA, at the increasing TFE concentrations. The corresponding curves for the 
ER-targeted tail-anchor peptide, L16 , are displayed in Figure 24B. Both peptides 
exhibit a-helical formation upon increasing concentrations of TFE. This is shown 
by the characteristic spectrum indicative of a-helical secondary structure, a 
maximum peak around 195nm and two minimum peaks around 209nm and 
222nm. In aqueous buffer and at a lower concentration of TFE, the spectra are 
indicative of random coil structure. Random coil secondary structure is depicted 
by a minimum peak around 195-200nm. In buffer containing 25% TFE, the 
MOA-tail peptide appears to have more helical formation than the L16-tail peptide 
(Figure 24C). This is evident from the increase in delta epsilon for the MOA-tail 
peptide at 192nm, characteristic of alpha helix formation. This is also illustrated 
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Figure 24. The mitochondrially targeted MOA-tail peptide has a higher 
propensity for TFE-induced a-helix formation than the ER-targeted peptide 
L 16. Synthetic peptides were dissolved in aqueous buffer containing the 
indicated amounts of TFE. Circular dichroism was measured as described in 
Materials and Methods. (A) MOA-tail peptide was measured with 0, 10%, 25%, 
40%, 50%, and 100% TFE. Results are reported as delta epsilon. (8) L 16 
peptide was measured as in panel (A). (C) The spectra for 25% TFE are shown 
in greater detail for comparison of MOA-tail peptide and the L 16 peptide. (0) The 
percent helical content, calculated as described in Materials and Methods, is 
plotted for the two peptides versus TFE concentration. 
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versus TFE concentration. Both peptides reached maximum helix formation in 
40% TFE. However, while MOA-tail peptide was highly helical (76%) in 25% 
TFE, L16-tail peptide was only slightly more helical (38%) than in completely 
aqueous buffer. This indicates that the mitochondrial-targeted tail-anchor peptide 
has a greater propensity to form helical structure in a helix-promoting solvent. 
These peptides exhibited similar behavior in OPC. The MOA-tail peptide 
exhibited helical formation even at the lowest concentration of 0.8mM OPC 
(Figure 25A). In contrast, the L16-tail peptide did not display helical formation 
until a higher concentration of 30mM OPC was used (Figure 25B). Percent 
helical content of these peptides at the various OPC concentrations is graphed in 
Figure 25C. As shown above, the MOA-tail peptide shows a higher propensity to 
form a helix in increasing concentrations of OPC, in comparison to the L16-tail 
peptide~ It should be noted that the concentrations of OPC were chosen in terms 
of the amount of micelle that is formed. The critical micelle concentration of OPC 
is 1.1 mM Stafford RE, 1989. At 0.8mM, OPC is entirely monomeric. At 3mM, there is 
more or less an even distribution of OPC in monomeric versus micelle form. At 
30mM, OPC is predominantly in micelles. Therefore, while the MOA-tail peptide 
exhibits a tendency to form helix in the presence of monomeric OPC, the L16-tail 
peptide does not. However, both peptides display helical formation in the 
presence of micellar OPC. A summary of these data are represented in Table 3. 
Comparisons of the percent helicity in the various solutions demonstrate an 
increased propensity of the MOA-tail peptide to form helix compared to the L16-
tail peptide. 
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As the data indicate, the mitochondrial-targeted tail-anchor peptide more 
readily forms a-helical secondary structure in comparison to the ER-targeted tail-
anchor peptide. This illustrates divergent biophysical properties that could 
account for the differential targeting of these tail-anchor sequences. In the 
context of physiological tail-anchored proteins, the translocation to differential 
membranes could depend partly on the helix-forming propensity of the various 
tail anchors. Future studies should expand this analysis by looking at larger 
subsets of mitochondrial- versus ER-targeted tail anchors. 
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Figure 25. The mitochondrially targeted MOA-tail peptide has a higher 
propensity for a-helix formation in the membrane mimetic OPC than the 
ER-targeted peptide L 16. Synthetic peptides were dissolved in aqueous buffer 
containing the indicated amounts of OPC. Circular dichroism was measured as 
described in Materials and Methods. (A) MOA-tail peptide was measured with 
O.3mM, 3mM, and 30mM OPC. Results are reported as delta epsilon. (8) L 16 
peptide was measured as in panel (A). (C) The percent helical content, 
calculated as described in Materials and Methods, is plotted for the two peptides 
versus OPC concentration. 
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TABLE 5. 
Table 5 Summary of alpha helix content of the indicated peptides in the solutions shown 
Solution MOA-tail % helix Lu,tail % helix 
Phosphate Buffer 18 21 
10% TFE 18 15 
25% TFE 76 38 
40% TFE 98 98 
50% TFE 98 95 
0.8mM ope 73 18 
3mM ope 99 51 
30mM ope 99 99 
Alpha helix content was calculated from the curves shown in Figs 12 and 13 as described in 
Materials and Methods. The remainder of the structure was almost exclusively random coil. 
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